Daniel J. DeAngelo

37.8k total citations · 7 hit papers
444 papers, 16.3k citations indexed

About

Daniel J. DeAngelo is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Daniel J. DeAngelo has authored 444 papers receiving a total of 16.3k indexed citations (citations by other indexed papers that have themselves been cited), including 269 papers in Hematology, 156 papers in Public Health, Environmental and Occupational Health and 130 papers in Molecular Biology. Recurrent topics in Daniel J. DeAngelo's work include Acute Myeloid Leukemia Research (168 papers), Acute Lymphoblastic Leukemia research (146 papers) and Chronic Myeloid Leukemia Treatments (119 papers). Daniel J. DeAngelo is often cited by papers focused on Acute Myeloid Leukemia Research (168 papers), Acute Lymphoblastic Leukemia research (146 papers) and Chronic Myeloid Leukemia Treatments (119 papers). Daniel J. DeAngelo collaborates with scholars based in United States, Germany and United Kingdom. Daniel J. DeAngelo's co-authors include Richard M. Stone, Martha Wadleigh, Ilene Galinsky, Anjali S. Advani, Wendy Stock, Donna Neuberg, Hagop M. Kantarjian, Robert J. Soiffer, D. Gary Gilliland and Erik Vandendries and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Daniel J. DeAngelo

430 papers receiving 16.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

2006 1.0k citations Ilene Galinsky, Daniel J. DeAngelo et al. profile →
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

2016 869 citations Hagop M. Kantarjian, Daniel J. DeAngelo et al. profile →
Differentiation and reversal of malignant changes in colon cancer through PPARγ

1998 865 citations Daniel J. DeAngelo et al. profile →
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

2009 604 citations Martha Wadleigh, Daniel J. DeAngelo et al. profile →
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

2014 595 citations R. Coleman Lindsley, Meir Wetzler et al. Blood profile →
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

2004 528 citations Richard M. Stone, Daniel J. DeAngelo et al. Blood profile →
Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

2023 139 citations Donna Neuberg, R. Coleman Lindsley et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel J. DeAngelo United States	60	9.0k	6.2k	4.3k	4.3k	3.9k	444	16.3k
Hervé Dombret France	67	13.5k 1.5×	7.2k 1.2×	6.1k 1.4×	4.1k 1.0×	3.7k 0.9×	377	18.9k
Elisabeth Paietta United States	61	7.8k 0.9×	4.7k 0.8×	4.3k 1.0×	3.0k 0.7×	2.6k 0.7×	278	12.9k
Tapan M. Kadia United States	57	9.8k 1.1×	5.4k 0.9×	3.0k 0.7×	2.7k 0.6×	3.9k 1.0×	778	13.2k
Sergio Amadori Italy	58	9.9k 1.1×	4.1k 0.7×	3.0k 0.7×	3.4k 0.8×	3.7k 0.9×	363	15.5k
Gautam Borthakur United States	65	13.2k 1.5×	6.7k 1.1×	3.3k 0.8×	2.9k 0.7×	6.5k 1.7×	809	17.7k
Wendy Stock United States	54	6.1k 0.7×	3.5k 0.6×	4.3k 1.0×	3.6k 0.9×	2.3k 0.6×	463	12.1k
Alan F. List United States	68	15.4k 1.7×	8.3k 1.3×	2.5k 0.6×	4.2k 1.0×	6.5k 1.7×	621	21.9k
Oliver G. Ottmann Germany	62	10.4k 1.1×	4.9k 0.8×	3.3k 0.8×	4.0k 0.9×	5.0k 1.3×	372	16.1k
Norbert Ifrah France	52	7.3k 0.8×	3.9k 0.6×	2.8k 0.7×	3.5k 0.8×	1.7k 0.4×	231	11.4k
Bayard L. Powell United States	60	9.7k 1.1×	5.7k 0.9×	3.3k 0.8×	2.8k 0.7×	2.9k 0.7×	260	14.2k

Countries citing papers authored by Daniel J. DeAngelo

Since Specialization

Citations

This map shows the geographic impact of Daniel J. DeAngelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. DeAngelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. DeAngelo more than expected).

Fields of papers citing papers by Daniel J. DeAngelo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. DeAngelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. DeAngelo. The network helps show where Daniel J. DeAngelo may publish in the future.

Co-authorship network of co-authors of Daniel J. DeAngelo

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. DeAngelo. A scholar is included among the top collaborators of Daniel J. DeAngelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. DeAngelo. Daniel J. DeAngelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2025). Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel). Transplantation and Cellular Therapy. 31(2). S216–S217. 1 indexed citations

Daver, Naval, Pau Montesinos, Daniel J. DeAngelo, et al.. (2024). Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. The Lancet Oncology. 25(3). 388–399. 34 indexed citations

Park, Jae H., Paul Shaughnessy, Aaron C. Logan, et al.. (2024). Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes. Blood. 144(Supplement 1). 963–963. 1 indexed citations

Winer, Eric S., Amit Verma, Katharina S. Götze, et al.. (2024). Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).. Journal of Clinical Oncology. 42(16_suppl). 6539–6539. 1 indexed citations

Daver, Naval, Pau Montesinos, Jessica K. Altman, et al.. (2024). A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.. Journal of Clinical Oncology. 42(16_suppl). TPS6585–TPS6585. 1 indexed citations

Metzeler, Klaus H., Uwe Platzbecker, Eric S. Winer, et al.. (2024). Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.. Journal of Clinical Oncology. 42(16_suppl). 6550–6550. 1 indexed citations

Chen, Evan C., Geoffrey Fell, Olga Pozdnyakova, et al.. (2022). Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. Clinical Cancer Research. 29(5). 878–887. 6 indexed citations

Kantarjian, Hagop M., Wendy Stock, Ryan D. Cassaday, et al.. (2021). Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research. 27(10). 2742–2754. 29 indexed citations

Stock, Wendy, Jae H. Park, Ashkan Emadi, et al.. (2021). Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood. 138(Supplement 1). 4406–4406. 1 indexed citations

10.

Zwicker, Jeffrey I., Tzu‐Fei Wang, Daniel J. DeAngelo, et al.. (2020). The prevention and management of asparaginase‐related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. Journal of Thrombosis and Haemostasis. 18(2). 278–284. 27 indexed citations

11.

Luskin, Marlise R., Angel M. Cronin, WooRam Jung, et al.. (2017). Spliceosome Mutations Are Associated with Frailty in Older Patients with Myeloid Malignancies. Blood. 130. 4276–4276. 1 indexed citations

12.

Cortes, Jörge E., Elie Traer, Eunice S. Wang, et al.. (2017). IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 130. 1312–1312. 7 indexed citations

13.

Nishi, Hiroshi, Kazuhiro Furuhashi, Xavier Culleré, et al.. (2017). Neutrophil FcγRIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. Journal of Clinical Investigation. 127(10). 3810–3826. 50 indexed citations

14.

Fathi, Amir T., Daniel J. DeAngelo, Kristen E. Stevenson, et al.. (2014). Intensified Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): A Phase II Study from the Dana Farber Cancer Institute (DFCI) ALL Consortium. Blood. 124(21). 3714–3714. 2 indexed citations

15.

Chonghaile, Tríona Ní, Justine E. Roderick, Jeremy Ryan, et al.. (2014). Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery. 4(9). 1074–1087. 190 indexed citations

16.

Adamia, Sophia, Benjamin Haibe‐Kains, Patrick M. Pilarski, et al.. (2013). A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets. Clinical Cancer Research. 20(5). 1135–1145. 79 indexed citations

17.

O’Brien, Susan, Camille N. Abboud, Mojtaba Akhtari, et al.. (2012). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 10(1). 64–110. 20 indexed citations

18.

Banerji, Versha, Stacey M. Frumm, Kenneth N. Ross, et al.. (2012). The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. Journal of Clinical Investigation. 122(3). 935–947. 85 indexed citations

19.

Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2010). Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology. 28(8). 1408–1414. 102 indexed citations

20.

DeAngelo, Daniel J., et al.. (1995). The Embryonic Enhancer-Binding Protein SSAP Contains a Novel DNA-Binding Domain Which Has Homology to Several RNA-Binding Proteins. Molecular and Cellular Biology. 15(3). 1254–1264. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact